Metabolomics During Testosterone Therapy
NCT01963390
Completed
One promising but understudied area in the field of testosterone (T) therapy is its effect on metabolism and the development of type II diabetes. Metabolomics is a powerful research tool that can detect very early signs of metabolic derangement that may lead to metabolic disease. In this observational study, investigators aim to apply metabolomics in order to better understand how T therapy influences metabolism. In a clinical population of outpatient men with T deficiency investigators will per... Read More
Gender:
MALE
Ages:
Between 20 years and 90 years
Trial Updated:
04/18/2018
Locations: Men's Health Boston, Chestnut Hill, Massachusetts
Conditions: Testosterone Deficiency
Register for Updates
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
NCT01686828
Completed
The purpose of this research study is to understand the effects of testosterone and estrogen on the body's response to the hormone insulin.
Gender:
MALE
Ages:
Between 25 years and 55 years
Trial Updated:
04/05/2018
Locations: University of Washington, Seattle, Washington
Conditions: Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Register for Updates
Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men
NCT00957801
Completed
Skeletal muscle loss is a common consequence of aging and in some individuals reaches a level that compromises health and quality of life. Age-associated increases in cytokine and inflammatory signaling may be important contributors to this process. The investigators will assess the practical question of whether testosterone injection and gel application elicit similar responses. Resistance exercise will be used as a means of stimulating both inflammatory and anabolic responses in skeletal musc... Read More
Gender:
MALE
Ages:
Between 60 years and 85 years
Trial Updated:
04/04/2018
Locations: The University of Texas Medical Branch at Galveston, Galveston, Texas
Conditions: Sarcopenia
Register for Updates
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
NCT02504541
Completed
Evaluation of safety of a concentration controlled testosterone enanthate QuickShot Testosterone regimen administered subcutaneously once each week to adult males with hypogonadism.
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
03/29/2018
Locations: Not set, Birmingham, Alabama +19 locations
Conditions: Hypogonadism
Register for Updates
NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers
NCT00647868
Completed
In this study the serum concentration of testosterone and its main metabolite DHT will be measured in hypogonadal men using intranasal testosterone (Nasobol). Different treatment regimens (once and twice daily) and administration times will be tested. The serum levels obtained will be compared with those of healthy men. It is expected that intranasal administration of Nasobol will restore testosterone and DHT levels to nearly normal.
Gender:
MALE
Ages:
Between 20 years and 60 years
Trial Updated:
03/29/2018
Locations: Harbor - UCLA Medical Center, Torrance, California
Conditions: Hypogonadism
Register for Updates
Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease
NCT01578473
Completed
Two recent studies have identified low levels of serum testosterone in association with Peyronie's Disease (PD), with a significant correlation noted between severity of testosterone deficiency and severity of curvature. The study hypothesis is to determine whether treatment with testosterone may help men with PD and penile curvature.
Gender:
MALE
Ages:
Between 18 years and 70 years
Trial Updated:
03/26/2018
Locations: Men's Health Boston, Chestnut Hill, Massachusetts
Conditions: Peyronie's Disease
Register for Updates
Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
NCT00878995
Completed
RATIONALE: Testosterone may lessen weight loss and improve muscle size and strength in patients with cachexia caused by cancer. PURPOSE: This randomized phase I trial is studying whether testosterone administered during standard of care chemotherapy and/or radiation works by helping patients with squamous cell carcinoma to maintain their body weight and muscle size and strength during treatment.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
03/08/2018
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Cachexia, Squamous Cell Carcinoma
Register for Updates
Testosterone and Physical Function in HIV+ Men
NCT00260143
Completed
Men infected with the HIV virus (the virus that causes AIDS) often lose weight even though they may try to eat more food to gain weight. The reasons for this weight loss are not clear. Many men with HIV have low levels of testosterone in their blood. Testosterone is a hormone that is naturally produced in the bodies of both men and women and has important effects on building muscle and bone mass. The purpose of this study is to find out if providing additional testosterone to HIV infected men wh... Read More
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
03/07/2018
Locations: Charles R. Drew University, Los Angeles, California
Conditions: HIV Associate Weight Loss
Register for Updates
Phlebotomy Study of Testosterone Undecanoate
NCT02670343
Completed
An open-label, single oral TU dose study was conducted in eight (8) hypogonadal men at a single study site. Each study participant received a single oral TU dose immediately prior to a standardized breakfast meal comprised of 800 to 1000 calories and approximately 30 g of fat. Blood samples were collected 30 minutes prior dose administration and at 0 pre-dose and post dose at the following hours post-dose; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours.
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
02/23/2018
Locations: Los Angeles Biomedical Research Institute, Torrance, California
Conditions: Hypogonadism
Register for Updates
Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism
NCT02777242
Completed
Evaluation of the safety and tolerability of testosterone enanthate (TE) following a single dose via QuickShot® Testosterone (QST) when administered by intended users in a usability study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/23/2018
Locations: Not set, Birmingham, Alabama +2 locations
Conditions: Hypogonadism
Register for Updates
Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
NCT02994602
Completed
This is a two-center, open-label study conducted in healthy male and female volunteers at two academic research centers. The study will consist of three single applications of the Nestorone (NES) + testosterone (T) combined gel on the shoulders/upper arms of male participants followed 2 hours later by supervised skin contact by the non-dosed female participants on the application site on days 1, 8, and 15. Effect of Washing or Clothing Barrier to the Application will be assessed.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
02/22/2018
Locations: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California +1 locations
Conditions: Healthy Men, Male Contraception, Healthy Women, Product Transference
Register for Updates
A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
NCT02722278
Completed
A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
01/24/2018
Locations: Multiple Sites in the United States, Northbrook, Illinois
Conditions: Hypogonadism
Register for Updates